Literature DB >> 29607928

Mechanisms of the pH- and Oxygen-Dependent Oxidation Activities of Artesunate.

Katsunori Tsuda1, Licht Miyamoto1, Shuichi Hamano2, Yuri Morimoto3, Yumi Kangawa3, Chika Fukue3, Yoko Kagawa3, Yuya Horinouchi4, Wenting Xu1, Yasumasa Ikeda4, Toshiaki Tamaki4, Koichiro Tsuchiya1.   

Abstract

Artemisinin was discovered in 1971 as a constituent of the wormwood genus plant (Artemisia annua). This plant has been used as an herbal medicine to treat malaria since ancient times. The compound artemisinin has a sesquiterpene lactone bearing a peroxide group that offers its biological activity. In addition to anti-malarial activity, artemisinin derivatives have been reported to exert antitumor activity in cancer cells, and have attracted attention as potential anti-cancer drugs. Mechanisms that might explain the antitumor activities of artemisinin derivatives reportedly induction of apoptosis, angiogenesis inhibitory effects, inhibition of hypoxia-inducible factor-1α (HIF-1α) activation, and direct DNA injury. Reactive oxygen species (ROS) generation is involved in many cases. However, little is known about the mechanism of ROS formation from artemisinin derivatives and what types of ROS are produced. Therefore, we investigated the iron-induced ROS formation mechanism by using artesunate, a water-soluble artemisinin derivative, which is thought to be the underlying mechanism involved in artesunate-mediated cell death. The ROS generated by the coexistence of iron(II), artesunate, and molecular oxygen was a hydroxyl radical or hydroxyl radical-like ROS. Artesunate can reduce iron(III) to iron(II), which enables generation of ROS irrespective of the iron valence. We found that reduction from iron(III) to iron(II) was activated in the acidic rather than the neutral region and was proportional to the hydrogen ion concentration.

Entities:  

Keywords:  artesunate; cancer; electron paramagnetic resonance (EPR); iron; reactive oxygen species (ROS)

Mesh:

Substances:

Year:  2018        PMID: 29607928     DOI: 10.1248/bpb.b17-00855

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

1.  Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons.

Authors:  Yize Li; Jiamin Kang; Ying Xu; Nan Li; Yang Jiao; Chenxu Wang; Chunyan Wang; Guolin Wang; Yonghao Yu; Jingjing Yuan; Linlin Zhang
Journal:  Front Mol Neurosci       Date:  2022-05-27       Impact factor: 6.261

Review 2.  Potential applications of artemisinins in ocular diseases.

Authors:  Bing-Wen Lu; Li-Ke Xie
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

3.  Artesunate exerts protective effects against ulcerative colitis via suppressing Toll‑like receptor 4 and its downstream nuclear factor‑κB signaling pathways.

Authors:  Yu-Xuan Chen; Xiao-Qi Zhang; Cheng-Gong Yu; Shu-Ling Huang; Ying Xie; Xiao-Tan Dou; Wen-Jia Liu; Xiao-Ping Zou
Journal:  Mol Med Rep       Date:  2019-06-05       Impact factor: 2.952

4.  Effect of artesunate and relation with TGF-β1 and SMAD3 signaling on experimental hypertrophic scar model in rabbit ear.

Authors:  Xiaolin Nong; Girju Rajbanshi; Ling Chen; Jiaquan Li; Zhan Li; Taotao Liu; Shihai Chen; Gao Wei; Jushang Li
Journal:  Arch Dermatol Res       Date:  2019-08-09       Impact factor: 3.017

5.  Quantitative evaluation of SARS-CoV-2 inactivation using a deep ultraviolet light-emitting diode.

Authors:  Takeo Minamikawa; Takaaki Koma; Akihiro Suzuki; Takahiko Mizuno; Kentaro Nagamatsu; Hideki Arimochi; Koichiro Tsuchiya; Kaoru Matsuoka; Takeshi Yasui; Koji Yasutomo; Masako Nomaguchi
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

6.  KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer.

Authors:  Kristen S Hill; Anthony McDowell; J Robert McCorkle; Erin Schuler; Sally R Ellingson; Rina Plattner; Jill M Kolesar
Journal:  Cancers (Basel)       Date:  2021-04-14       Impact factor: 6.639

7.  Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner.

Authors:  Xinyu Zhou; Abel Soto-Gamez; Fleur Nijdam; Rita Setroikromo; Wim J Quax
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.